Call Now: +1 858 800 3101 Email: info@innopep.com
Shopping Cart
0 Item(s) - $0.00
Your shopping cart is empty!
Cetrorelix Acetate, Cetrotide
| Overview | |
|---|---|
| Description | A highly modified luteinizing hormone-releasing hormone (LHRH) decapeptide with a terminal amide group, this peptide is a LHRH antagonist. It regulates the expression of Galphas and Galphai protein subunits and adenylate cyclase activity in ovary, breast and pituitary. Cetrorelix competitively inhibits LHRH receptor in the pituitary gland to suppress ovarian and testicular functions. |
| Sequence | Ac-{d-A[3-(2-naphthyl)]}-[d-F(4-Cl)]-{d-A[3-(3-pyridyl)]}-SY-(d-Cit)-LRP-d-A-NH2 €¢Acetate |
| Sequence (3 Letter) | Ac - {D - Ala[3 - (2 - naphthyl)]} - [D - Phe(4 - Cl)] - {D - Ala[3 - (3 - pyridyl)]} - Ser - Tyr - (D - Cit) - Leu - Arg - Pro - D - Ala - NH2 €¢ Acetate |
| Molecular Weight | 1431.2 |
| Properties | |
| Purity | % Peak Area By HPLC ≥ 95% |
| Storage | -20 °C |
Ref: Collado, B. et al. Intl. J. Oncol. 24, 725 (2004); Schwahn, M. et al. Drug Metabolism and Disposition. 28, 10 (2000).
About InnoPep
InnoPep Inc. is a company started by a couple of researchers with decades of expertise in peptide synthesis and conjugation aimed at enabling.